Articles

The rapid emergence of glucagon-like peptide-1 receptor agonists (GLP-1s), specifically semaglutide and the brand name Ozempic, has changed how we manage diabetes and obesity; these drugs must also be integrated with a lifestyle medicine methodology to ensure their continued success. Now pharmacotherapy is being used synergistically with a combination of personal nutrition, precise hydration, and behavior based treatment techniques to ensure continued metabolic health. In addition to decreasing the desire to eat, GLP-1 medications alter the interaction between the gut and brain, and how the body stores fat, which has implications for lean muscle mass, micronutrient status, and hydration status. The proposed framework helps us see GLP-1 medications as tools to promote metabolic health, rather than just isolated drugs that can be used to treat one condition, while providing the potential for equitable and resilient health care. As a collective force, this integrated approach allows for long-term success, regardless of population differences.